STAT Plus: Top FDA official: Agency needs to start using accelerated approval for gene therapies
FDA's Peter Marks said the oft-debated path used for some cancer drugs should be extended to gene therapies for rare diseases.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
STAT Plus: Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA filing plans
STAT Plus: Watch: P-value, an important measurement in clinical trials, explained
STAT Plus: Moderna CEO made $398 million in 2022, but still pledges to give most to charity
STAT Plus: FDA to convene advisory panel for Sarepta’s gene therapy for Duchenne
All Coverage
advertisement
